ALX Oncology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

• ALX Oncology Holdings Inc ALXO.OQ reported a quarterly adjusted loss of 58 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -71 cents. The mean expectation of five analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -59 cents to -31 cents per share.

• Reported revenue was zero​; analysts expected zero.

• ALX Oncology Holdings Inc's reported EPS for the quarter was a loss of 58 cents​.

• The company reported a quarterly loss of $30.75 million.

• ALX Oncology Holdings Inc shares had fallen by 22.3% this quarter and lost 71.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 34.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $4.00

This summary was machine generated from LSEG data May 8 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)